Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MBP-426 + leucovorin + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- Mebiopharm
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
A three-drug combination regimen consisting of **MBP-426** (a transferrin-conjugated liposomal formulation of oxaliplatin), **leucovorin** (folinic acid), and **5-fluorouracil** used in the treatment of advanced or metastatic solid tumors, particularly for gastrointestinal cancers such as gastric, gastro-esophageal, or esophageal adenocarcinoma. MBP-426 is designed for enhanced tumor targeting via transferrin receptor-mediated uptake and the enhanced permeability and retention effect, potentially reducing neurotoxicity seen with standard oxaliplatin. Its mechanism involves DNA crosslinking by oxaliplatin, while 5-fluorouracil inhibits thymidylate synthase and leucovorin potentiates 5-FU cytotoxicity[2][7][8].
- Brand names
- None
- Other names
- oxaliplatin liposome transferrin-conjugated + leucovorin + 5-fluorouracilMBP426 + LV + 5-FU
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on MBP-426 + leucovorin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MBP-426 + leucovorin + 5-fluorouracil.